Company news
Monte Rosa Therapeutics, Inc. news in 2022
Monte Rosa Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Monte Rosa Therapeutics Reports Third Quarter 2022 Financial Results and Business Updates
November 9, 2022
Monte Rosa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating MRT-2359, a GSPT1-directed Molecular Glue Degrader, for Treatment of MYC-driven Tumors
October 31, 2022
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences
October 30, 2022
Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader
September 5, 2022
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
August 10, 2022
Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates
May 10, 2022
Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022
April 7, 2022
Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates
March 28, 2022
Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders
January 24, 2022
Decks in 2022
- MRT-2359 KOL Webinar hosted by Cowen (October 2022)
Conference · 25 slides · Oct 24, 2022
- 2nd Annual TPD Europe Summit (March 2022)
Conference · 19 slides · Mar 17, 2022
- Investor Presentation (January 2022)
Investor deck · 41 slides · Jan 10, 2022